Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KetoFLEX 12/3 Diet and Cognitive Health: A Precision-Nutrition Perspective on Mechanisms, Emerging Evidence, and Future Directions.

Nutrients·2026
Same author

Preoperative Anemia and Perioperative Outcomes in Children: Prevalence, Risk Factors, and Associations in an Australian Cohort.

Paediatric anaesthesia·2026
Same author

Machine Learning Models with a Reject Option to Minimize Prediction Error: Application to Optical Properties of Dye Molecules.

Research square·2026
Same author

Admixture of anaesthetic drugs: editorial fit and safety are distinct concerns.

Journal of clinical monitoring and computing·2026
Same author

Jagged ligand expression by alpha-SMA progenitors is required for normal fracture healing.

Bone·2026
Same author

Scientific knowledge graph and ontology generation using open large language models.

Digital discovery·2026

Related Experiment Video

Updated: May 6, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.4K

Neuroprotective Sirtuin ratio reversed by ApoE4.

Veena Theendakara1, Alexander Patent, Clare A Peters Libeu

  • 1The Buck Institute for Research on Aging, Novato, CA 94945.

Proceedings of the National Academy of Sciences of the United States of America
|October 23, 2013
PubMed
Summary

The apolipoprotein E ε4 allele (ApoE4) promotes Alzheimer's disease by altering key protein ratios, leading to neuronal damage. Novel drug candidates targeting the ApoE-APP interaction show promise in restoring normal cellular function.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.4K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

11.7K

Related Experiment Videos

Last Updated: May 6, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.4K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.4K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

11.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Alzheimer's disease pathogenesis is linked to apolipoprotein E ε4 allele (ApoE4) expression, affecting amyloid precursor protein (APP) processing and Aβ peptide accumulation.
  • Existing mechanisms are incompletely defined, necessitating a multifactorial system for dissecting disease pathways and identifying therapeutics.

Purpose of the Study:

  • To investigate the differential effects of ApoE3 and ApoE4 on APP processing and neuronal health.
  • To develop a simplified system for evaluating multiple factors and pathways involved in Alzheimer's disease.
  • To identify potential drug candidates that modulate the ApoE-APP interaction.

Main Methods:

  • Comparative analysis of ApoE3 and ApoE4 interactions with APP.
  • Measurement of key protein ratios: sAPPα:Aβ, SirT1:SirT2, APP:p-APP, and Tau:p-Tau.
  • Assessment of programmed cell death induction.
  • Screening of drug candidates interfering with APP-ApoE binding.

Main Results:

  • Both ApoE3 and ApoE4 bind APP with high affinity, but only ApoE4 significantly alters sAPPα:Aβ ratios.
  • ApoE4 reduces Sirtuin T1 (SirT1) expression, creating an imbalance favoring neurotoxic SirT2.
  • ApoE4 induces Tau and APP phosphorylation and triggers programmed cell death.
  • Identified drug candidates successfully normalize these altered parameters by disrupting the APP-ApoE interaction.

Conclusions:

  • ApoE4 significantly disrupts neuronal connectivity by altering critical mediator ratios (sAPPα:Aβ, SirT1:SirT2, APP:p-APP, Tau:p-Tau).
  • The study presents a simplified system for identifying Alzheimer's disease mediators and therapeutic targets.
  • Targeting the APP-ApoE interaction offers a promising therapeutic strategy for Alzheimer's disease.